Russian Heart Failure Journal 2015year Do β-adrenoblockers improve prediction for CHF patients? – A clinical and genetic study in the Tatarstan Republic region

To access this material please log in or register

Register Authorize

Do β-adrenoblockers improve prediction for CHF patients? – A clinical and genetic study in the Tatarstan Republic region

Khazova E. V.1, Bulashova O. V.1, Gazizyanova V. M.1, Kravtsova O. A.2, Malkova M. I.1
1 - State Budgetary Educational Institution, "Kazan State Medical University" of the RF Ministry of Health Care, Butlerova 49, Kazan 420012
2 - Federal State Autonomous Educational Institution, "Kazan Federal University" of the RF Ministry of Health Care, Kremlevskaya 18, Kazan 420008

Keywords: beta-adrenergic blocker agents, treatment, prognosis, Republic of Tatarstan, CHF

DOI: 10.18087/rhfj.2015.2.2048

Background. At present, more than 20 placebo-controlled studies have demonstrated improved prediction and decreased mortality in patients with FC II–IV CHF receiving a drug therapy, which included β-blockers (BB). Nevertheless markers for unfavorable outcome in BB-treated patients have been continuously searched for. Aim. To analyze outcomes in CHF patients in the aspect of Arg16Gly and Gln27Glu polymorphisms in the ADRB2 gene and to evaluate the BB efficacy. Materials and methods. The study included 144 CHF patients of the hospital registry in the Tatarstan Republic region. Variants of ADRB2 Arg16Gly and Gln27Glu genes were determined. Information about cardiovascular events during one year of the study was considered. Endpoints included all-cause death, non-fatal MI and brain stroke (BS), hospitalization for decompensated CHF, and newly diagnosed diabetes mellitus (DM). Results. Irrespective of the variant of ADRB2 gene polymorphism, inclusion of BB into the drug complex improved the prediction by decreasing the number of fatal outcomes and non-fatal MI. At the same time, the BB treatment was associated with more cases of newly diagnosed DM with Arg16 / Arg genotype of the ADRB2 gene. Genotype Gly 16 Gly of the ADRB2 gene was found twice as frequently in patients receiving BB.
  1. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment ofAcute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14 (8):803–69.
  2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH / ESC Guidelines for the management of arterial hypertension: the Task Forse for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31 (7):1281–357.
  3. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34 (38):2949–3003.
  4. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2009;10 (2):64–103.
  5. Агеев Ф. Т. Бета-блокаторы: время испытаний или бремя испытаний? Проверка на прочность. Сердце. 2013;6 (74):345–54.
  6. Булашова О. В., Малкова М. И. Нужно ли применять β-адрено­блокаторы для снижения кардиального риска при выполнении внесердечных операций? Практическая медицина. Журнал для практикующих врачей. 2011;4 (52):18–21.
  7. CIBIS Investigators and Commitees. A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). Circulation. 1994 Oct;90 (4):1765–73.
  8. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet. 1999 Jan 2;353 (9146:9–13.
  9. Ghali JK, Piña IL, Gottlieb SS et al. Metoprolol CR / XL in female patients with heart failure analysis of the experience in metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002 Apr 2;105 (13):1585–91.
  10. Скворцов А. А., Мареев В. Ю. Бета-блокаторы при хронической сердечной недостаточности: какой тип бета-адренергической блокады предпочесть? Consilium Medicum. 2001;3 (2):79–82.
  11. Lopez-Sendon J, Swedberg K, McMurray JJ et al. Expert consensus document on b-adrenergic receptor blockers. Eur Heart J. 2004;25 (15):1341–62.
  12. Ольбинская Л. И., Сизова Ж. М. Особенности фармакотерапии артериальной гипертензии у больных хронической сердечной недостаточностью. Лечащий врач. 2007;3:42–6.
  13. Cleland JG, Pennell DJ, Ray SG et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003 Jul 5;362 (9377):14–21.
  14. Бадин Ю. В., Фомин И. В. Выживаемость больных ХСН в когортной выборке Нижегородской области (данные 1998–2002 годов.) Всероссийская конференция ОССН «Сердечная недостаточность-2005». – М., 2005. – С. 31–32.
  15. Jouven X, Empana JP, Schwartz PJ et al. Heart-rate profile during eхercise as a predictor of sudden death. N Engl J Med. 2005 May 12;352 (19):1951–8.
  16. Zuanetti G, Mantini L, Hernandez-Bernal F et al. Relevance of heart rate as a prognosticfactor in patients with acute myocardial infarction: insights fromthe GISSI-2 study. Eur Heart J. 1998 Jun;19 (Suppl F): F19–26.
  17. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the COoperative North Scandinavian ENalapril SUrvival Study (CONSENSUS). New Engl J Med. 1987 Jun 4;316 (23):1429–35.
  18. St John Sutton M, Pfeffer MA, Moye L et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction – baseline predictors and impact of long-term use of captopril: information from the Survival And Ventricular Enlargement (SAVE) trial. Circulation. 1997 Nov 18;96 (10):3294–9.
  19. The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med. 1992 Sep 3;327 (10):685–91.
  20. De Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI et al. Out-of-hospital cardiac arrest in the 1990’s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997 Nov 15;30 (6):1500–5.
  21. Exner DV, Dries DL, Waclawiw MA et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1999 Mar 15;33 (4):916–23.
  22. Freemantle N, Cleland J, Young P et al. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999 Jun 26;318 (7200):1730–7.
  23. Brodde OE. Beta1- and beta2‑adrenoceptor polymorphisms and cardiovascular diseases. Fundam Clin Pharmacol. 2008 Apr;22 (2):107–25.
  24. Liggett SB. The pharmacogenetics of beta2‑adrenergic receptors: relevance to asthma. J Allergy Clin Immunol. 2000 Feb;105 (2 Pt 2):S487–92.
  25. Jaillon P, Simon T. Genetic polymorphism of b2‑adrenergic receptor and mortality in ischemic heart disease. Therapie. 2007 Jan-Feb;62 (1):1–7.
  26. Sotoodehnia N, Siscovick DS, Vatta M et al. β2‑adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation. 2006 Apr 18;113 (15):1842–8.
  27. Kaye DM, Smirk B, Williams C et al. Beta-adrenoreceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics. 2003 Jul;13 (7):379–82.
  28. Арутюнов Г. П., Гончарова Л. Н., Постнов А. Ю. Генетические предикторы развития хронической сердечной недостаточности у больных артериальной гипертонией в популяциях Республики Мордовия. Журнал Сердечная Недостаточность. 2012;6 (74):355–64.
  29. Бровкин А. Н. Генетические факторы при сердечно-сосудистых заболеваниях: идентификация генов-кандидатов и фармакогенетика терапии бетаксололом. Автореф. дис. … канд. биол. наук. – М., 2010. – 21с.
  30. Kaye DM, Smirk B, Williams C et al. Beta-adrenoreceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics. 2003 Jul;13 (7):379–82. 31.
  31. Jia H, Sharma P, Hopper R et al. Beta2‑adrenoreceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians. J Hypertens. 2000 Jun;18 (6):687–93.
  32. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА–О–ХСН. Журнал Сердечная Недостаточность. 2006;7 (4):164–71.
  33. De Groote P, Isnard R, Assyag P et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail. 2007 Dec;9 (12):1205–11.
Khazova E. V., Bulashova O. V., Gazizyanova V. M. et al. Do β-adrenoblockers improve prediction for CHF patients? – A clinical and genetic study in the Tatarstan Republic region. Russian Heart Failure Journal. 2015;16 (2):106–111

To access this material please log in or register

Register Authorize
Ru En